About Shanghai Creation Investment
Shanghai Creation Investment is a venture capital firm founded in 2006. It is primarily based out of Shanghai, China. As of Jul 2021, Shanghai Creation Investment has invested in 25 companies. It primarily invests in Series B round in China based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series A round of Rui Bai Overall, Shanghai Creation Investment portfolio has seen 4 IPOs and 1 acquisition including key companies like Akeso, Cleveland HeartLab and Utilight. A lot of funds co-invest with Shanghai Creation Investment, with names like Zhongguancun Development Group sharing a substantial percentage of its portfolio. Shanghai Creation Investment has team of 8 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Rounds of Entry
Series A & Series B
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Shanghai Creation Investment's List of Top Investments
Shanghai Creation Investment has a portfolio of 25 companies. Their most notable investments are in Cygnus Bio and Shenyang Shenda Endoscope.Their portfolio spans across China, Israel and United States. They have invested in Life Sciences, High Tech, Enterprise Applications and 9 other sectors, across stages such as Series A, Series B stages. Here is the list of top investments by Shanghai Creation Investment:_1523881431192.png?format=webp&height=120&width=120)
1. Akeso
Developer of antibody drug conjugates for the treatment of broad spectrum diseases. The company utilizes proprietary Tetrabody technology to develop pipeline of products for cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields.
Key facts about Akeso
- Founded Year: 2012
- Location: Zhongshan (China)
- Stage: Public
- Total Funding till date: $195M
- Employee Count: 116 as on Aug 31, 2026
- Investors: CDG Capital, Loayal Valley Capital and 18 Others
- Latest Funding Round: Post IPO, Oct 13, 2024, $*****
- Highlight: Public
Surgical Theater enhances surgical precision using XR technology. It provides immersive XR experiences throughout a patient's surgical journey, from planning and rehearsal to the procedure itself. The platform offers tools for surgical planning, patient engagement, and improved OR visualization. These tools utilize patient-specific XR reconstructions to help surgeons visualize complex anatomy and potential risks, leading to better surgical outcomes. The technology also helps patients understand their procedures more effectively. This approach aims to improve surgical precision and patient outcomes.
Key facts about Surgical Theater
- Founded Year: 2010
- Location: Beachwood (United States)
- Stage: Series A
- Total Funding till date: $10.5M
- Employee Count: 85 as on Aug 31, 2026
- Investors: HTC Corporation, BLANCAP INVESTMENTS and 9 Others
- Latest Funding Round: Series A, Oct 19, 2015, $*****
Manufacturer of solar modules, energy storage systems, and EPC services. It offers a range of solar modules, including bifacial half-cell and single-glass options. The company also provides energy storage solutions and complete engineering, procurement, and construction (EPC) services for solar power projects. These services encompass the entire project lifecycle, from development to operation. Integrated rooftop systems are also part of their offerings.
Key facts about ZNShine PV-Tech
- Founded Year: 1998
- Location: Changzhou (China)
- Stage: Funding Raised
- Employee Count: 191 as on Aug 31, 2026
- Investors: Shanghai Creation Investment
- Highlight: Editors' Pick
Innovative cardiovascular biomarker testing for risk identification and disease prevention. They offer advanced biomarker testing services, including inflammatory markers, to aid clinicians in identifying cardiovascular risk and reducing events. The company focuses on innovation through research and development, partnering with institutions to bring unique biomarker technologies to market. They are committed to education, providing resources and events for healthcare providers and patients to understand cardiovascular risk. The company operates a CAP-accredited and CLIA-certified clinical reference laboratory, offering a pipeline of novel tests targeting under-addressed markets. Their services support the management and prevention of heart disease through evidence-based science and clinical testing. They provide solutions-oriented services with integrity, aiming to be a premier cardiovascular testing provider.
Key facts about Cleveland HeartLab
- Founded Year: 2008
- Location: Cleveland (United States)
- Stage: Acquired
- Total Funding till date: $38.9M
- Employee Count: 62 as on Aug 31, 2026
- Investors: Abundance Partners, Excel Venture Management and 9 Others
- Latest Funding Round: Series B, Jul 08, 2014, $*****
- Highlight: Acquired
5. Utilight
Utilight develops a 'Pattern Transfer Printing' technology which is a non-contact 3D laser printing technology used in the PV metallization process of c-Si solar cells (for establishing a electrical contact between different solar cells). This manufacturing increasing solar cell efficiency and reduces PV manufacturing costs.
Key facts about Utilight
- Founded Year: 2008
- Location: Yavne (Israel)
- Stage: Public
- Total Funding till date: $7.4M
- Employee Count: 24 as on Aug 31, 2026
- Investors: Robert Bosch Venture Capital, I2BF Global Ventures and 3 Others
- Latest Funding Round: Series A, Mar 07, 2016, $*****
- Highlight: Public
Shanghai Creation Investment's Year-on-Year Investment Trends
Shanghai Creation Investment has invested in 25 companies over the last 10 years, with an average of 0 new investment annually in the last 10 years. Its most recent first time investment was in Rui Bai.Shanghai Creation Investment's Investments by Stage
Shanghai Creation Investment has made 2 investments in Series A stage with an average round size of $2.9M and 2 investments in Series B stage with an average round size of $19.8M.Stage of entry | No. of Investments |
|---|---|
Series A | 2 |
Series B | 2 |
Note: We have considered here, only first round of investments
Shanghai Creation Investment's Investments by Sector
Shanghai Creation Investment has a diverse portfolio, with companies operating in the Life Sciences, Energy, Environment, Healthcare and High Tech. Notably, it has invested in 17 Enterprise (B2B) companies, 15 Tech companies, 8 Tech hardware companies and at least 4 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 2 |
Energy | 1 |
Environment | 1 |
Healthcare | 1 |
High Tech | 1 |
Note: We have considered here, only first round of investments
Shanghai Creation Investment's Investments by Geography
Shanghai Creation Investment has made most investments in China (3), followed by Israel where it has made 1 investment.Country | No. of Investments |
|---|---|
China | 3 |
Israel | 1 |
Note: We have considered here, only first round of investments
Shanghai Creation Investment's recent investments
Shanghai Creation Investment has not made any investment in 2026 so far.Here are the most recent investments by Shanghai Creation Investment:
Date | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jul 01, 2021 | China | Series A | 8355 | ||
Jan 18, 2021 | China | Series B | 4728 | ||
Nov 14, 2017 | China | Series B | 4542 | ||
Mar 07, 2016 | Israel | Series A | 2855 | [+2] |
IPOs and Publicly Listed companies in Shanghai Creation Investment's Portfolio
4 of Shanghai Creation Investment's portfolio companies have become public. Akeso got listed on the Hong Kong Exchanges (HKG), in Apr 2020 at marketcap of $1.59B and Guangzhou Shangpin Home Furnishing got listed on the Shenzhen Stock Exchange (SZSE) at marketcap of $850M.Here are Shanghai Creation Investment's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 24, 2020 | - | - | 5163 | |
Mar 07, 2017 | - | - | 5943 | |
Jan 21, 2014 | - | - | 5052 | |
- | Mar 07, 2016 | Series A | 2443 |
Acquired companies in Shanghai Creation Investment's Portfolio
1 company from Shanghai Creation Investment's portfolio has been acquired. The most recent acquisition was Cleveland HeartLab in Oct 2017 by Quest Diagnostics for $*****.Here are Shanghai Creation Investment's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 19, 2017 | - | - | 3408 |
Team profile of Shanghai Creation Investment
Shanghai Creation Investment has a team of 8 members including 2 Partners and 4 Principals located in China. Shanghai Creation Investment's team does not sit on the board of any company as of now.Here is a list of all team members in Shanghai Creation Investment:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | China | - | ||
Partner | Shanghai | - | - | |
Principal | Shanghai | - | - | |
Principal | Shanghai | - | - | |
Principal | Jing an | - | - | |
Principal | Chongqing | - |
Co-investors of Shanghai Creation Investment
Over the past 10 years, 17 investors have co-invested in Shanghai Creation Investment's portfolio companies. This includes funds and angels.
- Invested before Shanghai Creation Investment: I2BF Global Ventures, Waarde Capital and 1 other have invested in rounds before Shanghai Creation Investment. There is 1 company where I2BF Global Ventures has invested before Shanghai Creation Investment and 1 company where Waarde Capital has invested before Shanghai Creation Investment.
- Top Co-investors of Shanghai Creation Investment: 7 investors entered a company along with Shanghai Creation Investment. These include investors like Zhongguancun Development Group (1 company).
- Invested after Shanghai Creation Investment: A total of 7 investors have invested in Shanghai Creation Investment's portfolio after their investments. Top Investors include China Research Fund (1 company), Wuxi Guolian Guokang Health Industry Investment Center (1 company) and Source Code Capital (1 company).
Recent News related to Shanghai Creation Investment
•
Yike Medical completed nearly 100 million yuan of A round of financing, Shanghai Chuangrui led the investmentPEdaily•Jul 26, 2021•Shanghai Creation Investment
•
The developer of cerebrovascular interventional surgical instruments "Minor MicroPort" completes tens of millions of pre-A rounds of financing36Kr•Dec 30, 2020•Shanghai Creation Investment
•
Cygnus Raises $19.6M for Highly Accurate Sequencing TechnologyBioSpace•Nov 15, 2017•Cygnus Bio, Shanghai Creation Investment, Zhongguancun Development Group, Bjlp.lhygcn.com and 2 others
•
Utilight Raises $2.9M |FinSMEsFinSMEs•Mar 09, 2016•Utilight, I2BF Global Ventures, Robert Bosch Venture Capital, Shanghai Creation Investment and 1 other
•
3D Printing Firm Utilight Raises $3M | News FlashNoCamels•Mar 08, 2016•Utilight, I2BF Global Ventures, Robert Bosch Venture Capital, Shanghai Creation Investment and 1 other
•
Israeli 3D laser printing co Utilight raises $2.9m - Globes
Globes•Mar 07, 2016•Utilight, I2BF Global Ventures, Robert Bosch Venture Capital, Shanghai Creation Investment and 1 other
•
Venture Capital Access Online | Venture Capital NewsVCA Online•Oct 19, 2015•Surgical Theater, HTC Corporation, Shanghai Creation Investment
•
Surgical Theater Secures $9 Million Series A Financing Round Led by HTC and Shanghai Creation Investment Management Co, Ltd. (SCI)
Marketwired•Surgical Theater, HTC Corporation, Shanghai Creation Investment
